Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
PGET
Atrium Therapeutics
Osteoarthritis
1 trial -
PH94B
Vistagen Therapeutics
Social Anxiety Disorder
1 trial -
PH94B Nasal Spray
Vistagen Therapeutics
Social Anxiety Disorder
2 trials -
PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN
Tour Hekla
Recurrent Erysipelas in lower limbs
1 trial -
PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS
Sanofi-aventis Healthcare Pty Ltd
Dermatitis atopic
1 trial -
PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS
Sanofi-aventis Healthcare Pty Ltd
Dermatitis atopic
1 trial -
PL1 - Placebo to match losmapimod tablets are tablets for oral administration and visually match the active losmapimod tablets, 15 mg., Losmapimod
Fulcrum Therapeutics
Facioscapulohumeral Muscular Dystrophy (FSHD)
1 trial -
PL2200 Aspirin Capsules
Protalix BioTherapeutics
Diabetes Mellitus, Type 2
2 trials -
PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion
Pari Pharma GmbH
Patients hospitalized for allogeneic hematopoietic stem cell transplantation
1 trial -
PLACEBO for GIVINOSTAT hydrochloride monohydrate (ITF2357) 10 mg/mL oral suspension, ITF2357
Italfarmaco S.p.A.
Duchenne muscular dystrophy (DMD)
1 trial -
PLACEBO, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, DOMVANALIMAB
AstraZeneca AB
The target population of interest in this study is participants with locally advanced (Stage III), unresectable NSCLC, whose tumours express PD L1 TC ≥ 1% as assessed by a central reference laboratory using the VENTANA PD-L1 (SP263) IHC assay, and who did not progress after definitive platinum based cCRT.
1 trial -
PLENVU Pulver zur Herstellung einer Losung zum Einnehmen, SODIUM PICOSULFATE
Norgine Pty.
Colonic disease
1 trial -
PLX-200
Polaryx Therapeutics
Juvenile Neuronal Ceroid Lipofuscinosis
1 trial -
PREDNISOLONE, CORTISONE ACETATE, FLUDROCORTISONE, Gohibic, TRIAMCINOLONE, PREDNISONE, DEXAMETHASONE, HYDROCORTISONE, METHYLPREDNISOLONE, IFX-1 placebo is formulated as PBS (150 mM sodium chloride, 10 mM sodium phosphate, pH 7.0) with 0.05% polysorbate 80. IFX-1 placebo is diluted in sterile 0.9% sodium chloride to the required concentration and volume. This diluent is a commercial product not accompanying IFX-1 placebo., BETAMETHASONE
InflaRx GmbH
ulcerative pyoderma gangrenosum
1 trial -
PREDNISOLONE, Placebo for Depemokimab Injection, Placebo for Prednisolone
GlaxoSmithKline
Hypereosinophilic Syndrome (HES)
1 trial -
PREDNISOLONE, Placebo pMDI to match Budesonide/Formoterol Fumarate pMDI, Placebo MDI match Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, SALBUTAMOL
AstraZeneca AB
Severe and inadequately controlled asthma
1 trial -
PREDNISONE, PREDNISONE, SODIUM CHLORIDE, RITUXIMAB
Fondazione Telethon ETS
Generalized Myasthenia Gravis
1 trial -
PREDNISONE, SRP-9003, PREDNISONE, PREDNISONE
Sarepta Therapeutics
Limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4) or β-sarcoglycanopathy
1 trial -
PREVNAR 20 ®, Pneumococcal Conjugate Vaccine (PCV)
Sanofi-aventis Healthcare Pty Ltd
Pneumococcal immunisation
1 trial -
PRM-151 (Zinpentraxin Alfa)
Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
1 trial -
PRO 2000/5
United Therapeutics Europe Ltd
HIV Infections
1 trial -
PROGRAF 5 mg, gélule, PROGRAF 1 mg, gélule, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, PROGRAF 0,5 mg, gélule
Pari Pharma GmbH
Antisynthetase syndrome-related interstitial lung disease
1 trial -
PRX-102
Protalix BioTherapeutics
Fabry Disease
2 trials -
PRX-102 (pegunigalsidase alfa)
Protalix BioTherapeutics
Fabry Disease
3 trials
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources